open access
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered
Affiliations- Department of Anesthesia and Intensive Care, A.O.U. Policlinico-San Marco, Catania, Catania, Italy
open access
Abstract
Abstract
About this articleTitle
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered
Journal
Issue
Article type
Letter to the Editor
Pages
798-799
Published online
2021-07-07
Page views
11653
Article views/downloads
497
DOI
Pubmed
Bibliographic record
Cardiol J 2021;28(5):798-799.
Authors
Filippo Sanfilippo
Luigi La Via
Federica Merola
Marinella Astuto
References (5)- Jaguszewski MJ, Gasecka A, Targonski R, et al. Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiol J. 2021; 28(3): 492–493.
- Sanfilippo F, Knight JB, Scolletta S, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017; 21(1): 252.
- Afshari A, Wetterslev J. When may systematic reviews and meta-analyses be considered reliable? Eur J Anaesthesiol. 2015; 32(2): 85–87.
- Barili F, Parolari A, Kappetein PA, et al. Statistical Primer: heterogeneity, random- or fixed-effects model analyses? Interact Cardiovasc Thorac Surg. 2018; 27(3): 317–321.
- Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17): 1883–1891.
